ArticleCancer immunology, immunotherapy : CII2026
High PD-1 expression in pre-treatment peripheral lymphocytes associated with poor immune checkpoint inhibitor response in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade is the standard therapy for recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC), yet many patients exhibit poor responses. Potential non-invasive biomarkers for predicting treatment response in RMHNSCC remain unclear. In this study, we collected blood samples from 47 RMHNSCC patients and 17 healthy controls. PD-1 expression was evaluated using 10-color flow cytometry before treatment. Subpopulations of peripheral blood lymphocytes (PBLs) were assessed at baseline, 2-3 weeks, and 6 weeks after the first anti-PD-1 immune checkpoint inhibitor (ICI) treatment. A total of 116 patient samples were used for longitudinal comparison of treatment-induced changes in lymphocyte subpopulations. Patients had higher PD-1+ PBL levels than healthy individuals (25.0% vs. 20.3%, P = 0.006). Those with PD-1+ PBLs ≥ 25% exhibited elevated T cell levels and higher frequencies of PD-1+lymphocyte subsets expressing CD38 and HLA-DR concurrently or CD56/CD16, alongside reduced NK cell levels before anti-PD1 therapy. The median progression-free survival (PFS) was 2.2 months, with an overall one-year PFS rate of 18%. The patients with PD-1+ PBLs ≥ 25% showed significantly poorer one-year PFS (7% vs. 29%, P = 0.039) and overall survival rates (20% vs. 50%, P = 0.018) than the opposite group. Comparing fold changes from baseline, the patients with PD-1+PBLs ≥ 25% showed significantly lower increases in CD4+CD38+HLA-DR +T cells (median: 1.15 vs. 1.66 at the first post-treatment test), and CD8+CD38 + HLA-DR + T cells (medians: 1.01 vs. 1.34 and 1.23 vs. 1.78 at the first and second post-treatment tests, respectively) compared to the opposing group. Our findings indicate that high PD-1 expression in PBLs predicts poor treatment outcomes for anti-PD-1 ICIs in patients with RMHNSCC. Dynamic immune monitoring can assist physicians in tailoring personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.